MC Riddle - Endocrinology and metabolism clinics of North America, 2005 - Elsevier We have long known, but now understand more fully that type 2 diabetes is common,
complex, and as treated presently, leads to severe medical consequences. In type 1
diabetes, hyperglycemia is the leading cause of harm. In type 2 diabetes, despite a well- ... Cited by 68 - Related articles - All 3 versions
P Home - Current Medical Research and Opinion®, 2005 - informahealthcare.com University of Newcastle upon Tyne, Newcastle upon Tyne, UK ... Address for
correspondence: Professor Philip Home, School of Clinical Medical Sciences – Diabetes, The
Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK. Tel: +44 191 ... Cited by 51 - Related articles - All 6 versions
E Bonora, G Corrao, V Bagnardi, A Ceriello, M … - Diabetologia, 2006 - Springer Abstract Aims/hypothesis: Post-prandial glucose may be a risk factor for cardiovascular disease
and chronic diabetic complications. We tested the hypothesis that post-prandial hyperglycaemia
is common in type 2 diabetes, even among patients in apparently good glycaemic control, ... Cited by 47 - Related articles - BL Direct - All 3 versions
- ►columbiauniversity.org [PDF] B Kimmel, SE Inzucchi - Clinical Diabetes, 2005 - Am Diabetes Assoc Type 2 diabetes is a multifactorial metabolic disease characterized by abnormalities at multiple
organ sites. These defects include insulin resistance and insulin deficiency. 1,2 The former is
primarily represented by decreased insulin-stimulated glucose uptake in skeletal muscle, ... Cited by 46 - Related articles - All 5 versions
AR Vasudevan, A Balasubramanyam - Diabetes Technology & …, 2004 - liebertonline.com The thiazolidinediones (TZDs) rosiglitazone and pioglitazone are newer additions to the an-
tidiabetic armamentarium and are indicated for the treatment of type 2 diabetes mellitus
(T2DM) in the United States. The TZDs are peroxisome proliferator-activated receptor- ( ... Cited by 45 - Related articles - All 3 versions
IW Campbell - International Journal of Clinical Practice, 2005 - medscape.com Therapy for type 2 diabetes mellitus should aim to control not only fasting, but also postprandial
glucose levels. Nateglinide, a d-phenylalanine derivative, restores postprandial early phase
insulin secretion in a transient and glucose-sensitive manner without affecting basal ... Cited by 15 - Related articles - BL Direct - All 6 versions
JF Blickle - Diabetes and Metabolism, 2006 - Elsevier Glinides represent a chemically heterogeneous new class of insulinsecreting agents characterized
by a rapid onset and short duration of action. They act by closure of the ATP-dependant K
channel. Repaglinide, the only glinide available in France, has an equivalent HbA 1c ... Cited by 16 - Related articles - BL Direct - All 3 versions
- ►nursing2008.com V Bhatia - SOUTHERN MEDICAL JOURNAL-BIRMINGHAM …, 2005 - pdfs.journals.lww.com Abstract: The classic polycystic ovarian syndrome (PCOS) was originally described by Stein
and Leventhal as the association of amenorrhea with polycystic ovaries and, variably, hirsutism
and/or obesity. It is estimated that 5 to 10% of women of reproductive age have PCOS. ... Cited by 14 - Related articles - BL Direct - All 13 versions
L Monnier, M Benichou, S Charra-Ebrard, C … - Diabetes and Metabolism, 2005 - Elsevier Therapeutic strategies in type 2 diabetic patients should not only integrate both the targets and
indications of the different therapies but should be also a compromise between the patient's and
physician's goals and willingnesses. The rationale for therapeutic targets is based on ... Cited by 10 - Related articles - All 4 versions
AG Arno, JF NADAL, MM CASES - Medicina clinica(Ed. impresa), 2004 - cat.inist.fr Criterios de control y pautas de tratamiento combinado en la diabetes tipo 2.
ActualizaciÓn 2004. Alberto Goday ARNO, Josep Franch NADAL, Manuel Mata CASES
Medicina clinica(Ed. impresa) 123:55, 187-197, Doyma, 2004.
Cited by 17 - Related articles - All 3 versions
